Biogen Idec moves forward with trials
Biogen Idec has successfully completed phase 1 and 2a safety trials of its new hemophilia B treatment rFIXFc and has begun phase 3 trials.
The Weston, Mass.-based company (NASDAQ: BIIB) has developed the new drug with Swedish company Orphan Biovitrum AB (STO: SOBI).
The treatment has the potential to improve the lives of hemophilia patients by reducing the frequency of medication doses. Current treatments require patients to receive intravenous injections two times a week, but Biogen’s latest treatment could cut that to once a week payday loans for bad credit. That “ … would be an important advancement for the hemophilia community,” says Dr. Amy Shapiro, medical director of the Indiana Hemophilia and Thrombosis Center.
Biogen Idec employs about 850 people at its manufacturing facility in Research Triangle Park, where the company manufactures multiple sclerosis drugs Tysabri and Avonex.
Filed under: term by Finance Boss